HBM Healthcare Investments - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

Sareum Holdings

MCap

GBP35m

Last close

GBP0.34

▲ 10.25 (44.09%)

Pharnext

MCap

1m

Last close

EUR0.10

▲ 0.03 (42.86%)

VolitionRx

MCap

USD70m

Last close

USD0.85

▲ 0.25 (41.67%)
Sectors
Sectors
Investment Strategy
Investment Strategy
View All

Latest
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

James Brotherton Financial Director — Tyman
Equity Research
Investor Relations
Contact us

Overview
Price performance
Financials
Research
Thematics

HBMN aims to generate long-term capital gains through direct investments in emerging private and public companies in biotechnology, human medicine, diagnostics, medical technology and related areas.

Latest Insights

View More

Investment Companies |
Review

25.05.22

HBM Healthcare Investments — Looking ahead to renewed opportunities

Investment Companies |
Review

03.06.21

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies |
Flash note

04.02.21

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn

Investment Companies |
Review

25.03.20

HBM Healthcare Investments — Keeping calm amid the market turmoil

Sector

Investment Companies

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	(1.0)	(12.1)	(14.5)
Relative	(6.0)	(12.4)	(9.3)
52 week high/low	€275.0/€192.2

Overview

HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).

Research

Investment Companies

Initiation

HBM Healthcare Investments — Update 25 February 2016

Initiation

Investment Companies

26.02.16

HBM Healthcare Investments — Update 25 February 2016

thematic

Investment Companies

30.11.22

Investment companies: Latin America is worthy of consideration

thematic

Consumer

05.10.22

IPO apocalypse

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Investment Companies

10.05.22

The case for US capital markets

thematic

Investment Companies

07.12.20

Value Investing: Living with the reality, waiting for the inevitable

thematic

Consumer

14.08.19

Illuminator: August Update

thematic

Investment Companies

07.08.19

Post Woodford- A spotlight on smaller company liquidity

thematic

Investment Companies

05.06.19

How to buy and sell investment trusts

thematic

Investment Companies

26.03.19

Types of investment trusts

thematic

Consumer

11.11.14

Deutsche Börse Eigenkapitalforum 2014 Research Guide

thematic

Investment Companies

24.05.12

Investment Trusts Quarterly: Biotechnology & healthcare trusts

thematic

Investment Companies

13.01.12

Investment Trusts Quarterly: Growth and income